AzTrials
AzTrials

SchwannomaNCT01951365

Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma

An observational study of Schwannoma and Neurinoma, run by Seoul National University Hospital at 2 sites in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Spinal intradural schwannoma detected incidentally increased recently. Because there is little knowledge about natural history of spinal schwannoma, there is no consensus of treatment. Our hypothesis is as follows; 1. Some schwannomas keep growing, the others do not. 2. Foraminal schwannomas do not usually grow. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Schwannoma, Neurinoma
How many people
56 participants
Where
2 sitesSouth Korea
Study dates
Jun 1998to Aug 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients diagnosed of spinal IDEM schwannoma in 2 institutes

Who may be able to join

  • All patients who were diagnosed of spinal IDEM schwannoma by MR imaging and checked follow-up MR imaging not undergoing surgical resection (including radiosurgery).

Who cannot join

  • 1) surgical resection at the diagnosis; 2) von Recklinghausen' disease (neurofibromatosis); and 3) recurred or residual tumor.

Trial locations and contacts

2 sites in 1 country.

South Korea2 sites
  • Seoul National University Bundang Hospital

    Seongnam, Kyenggi, 110-769

  • Seoul Natl. Univ. Hospital

    Seoul, 110-769

Other trials in South Korea

About this study

Official title: Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History

Spinal intradural schwannoma detected incidentally increased recently. Because there is little knowledge about natural history of spinal schwannoma, there is no consensus of treatment. Our hypothesis is as follows;

  1. Some schwannomas keep growing, the others do not.
  2. Foraminal schwannomas do not usually grow.

The investigators analyzed natural history and characteristics of 56 spinal schwannomas observed initially with accurate and reliable methods. Here the investigators displayed growing pattern and differential point of spinal schwannoma.

Read the detailed description

Study design and participants

The investigators included all patients who were diagnosed of spinal IDEM schwannoma by MR imaging and checked follow-up MR imaging not undergoing surgical resection (including radiosurgery). The patients usually checked follow-up MR imaging annually or biannually. The patients who underwent surgical resection during the surveillance interval were also enrolled.

Exclusion criteria of this study were as follows: 1) surgical resection at the diagnosis; 2) von Recklinghausen' disease (neurofibromatosis); and 3) recurred or residual tumor. For patients lost follow-up, the investigators checked whether the patients underwent a surgery or not by telephone and obtained recent radiologic studies as possible.

Medical record and radiologic studies of enrolled patients were evaluated for patient demographics, tumor level, main location (intracanal or foraminal), shape (globus, rugby ball, or dumbbell), date at diagnosis, follow-up date at check follow-up MR imaging, and length of follow-up. These serial studies were compared with tumor growth to evaluate for any correlation.

Tumor volume measurement and growth

The investigators measured tumor volume by volume quantification method using the Leksell Gamma Plan® system (version, 10.1.1. Elekta Instrument AB, Stockholm, Sweden) in Figure 1. It calculates tumor volume by summation of cylindrical masses from each image and has an advantage to measure with the best accuracy especially non-globus tumor.6 The process of measuring tumor volume was rigorously designed to minimize observer subjectivity. Stack images without gap were loaded to the program. The investigators draw the tumor outlining by manually in select planes of each orthogonal view. The program measures tumor volume using an algorithm based on scattered data interpolation with radial basis functions. All tumor volumes were measured independently by two observers. Interobserver reliabilities were assessed by the Brand-Altman plot. The plot was applied to look for trends in the data that produce similar results and to evaluate the agreement between two observers.7 Under the confidence of excellent interobserver agreement marks, the investigators finally estimated the tumor volume as the mean value of two measured data.

Volumetric growth rate (VGR) of the tumor was calculated volume change to the baseline volume and presented in percent. Overall VGR (%) was calculated using the following formula: (Final volume-Baseline volume)x100/Baseline volume. Annual VGR (%) was calculated as follows; Annual VGR (%)=(Final vol.-Baseline vol.)/(Baseline vol.)*FU duration(days)*12/365*100 FU and vol. mean follow-up and volume, respectively. There is no consensus about definition and amount of tumor growth. A prior study reported that the cut-off value of growth rate of vestibular schwannoma extending into the cerebello-pontine angle was 10.4%. The investigators set 10% increase of VGR as a cut-off value. The investigators made two standards, 10% increase of overall and annual VGR, and evaluate validity by the receiver operating characteristic (ROC) curve. Enrolled patients were divided into two groups by the standard. The first group, growing tumor, was defined as mean ≥10% increase of tumor volume. The other group, stable tumor, was defined as mean <10% increase, stationary, or decrease of tumor volume.

Statistical analysis

The investigators used the Brand-Altman plot for interobserver reliability. The investigators used the ROC analysis to compare predictive validity of standards by overall VGR and annual VGR, and to find out their optimal cut-off values of annual VGR in growing schwannomas. Because the area under the curve is a measure of the diagnostic power of a test, larger one is chosen as a standard dividing growing versus stable tumor. ROC curves were plotted using measures of sensitivity and specificity based on various cut-off values. Cut-off value was selected as the values closer to the upper left corner. For comparative analyses between the growing and stable tumor group, independent t tests for continuous variables, Fisher's exact test, and chi-square test were used. The significance level was set at p < 0.05. The investigators used MedCalc Statistical Software version 12.7.2 (MedCalc Software bvba, Ostend, Belgium) for the Bland-Altman plot and the SPSS statistical package (Version 20.0; SPSS Inc, Chicago, IL, USA) for the other data analysis.

Keywords
Schwannoma, Growth, intradural, natural history
Medical subject headings
Neurilemmoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01951365
Study groupRoleWhat they receive
Growing schwannomaOverall volumetric growth rate more over than 10%
Stable schwannomaOverall volumetric growth rate less than 10%

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Volumetric growth rate

    Measured: 12, 24, 36, 48, 72, 96,120,144 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2013 (estimated)
  2. Study startJun 1998
  3. Primary completionFeb 2012
  4. Study completionAug 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01951365
Sponsor's protocol ID
SNUNS-spine-01
Status last verified
Sep 2013
First submitted
15 Sep 2013
Last updated
26 Sep 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Schwannoma and Neurinoma, run by Seoul National University Hospital at 2 sites in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Sep 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Volumetric growth rate (time frame: 12, 24, 36, 48, 72, 96,120,144 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in